These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 33643034)

  • 1. Development of a Physiologically Based Pharmacokinetic Model for Hydroxychloroquine and Its Application in Dose Optimization in Specific COVID-19 Patients.
    Zhang M; Yao X; Hou Z; Guo X; Tu S; Lei Z; Yu Z; Liu X; Cui C; Chen X; Shen N; Song C; Qiao J; Xiang X; Li H; Liu D
    Front Pharmacol; 2020; 11():585021. PubMed ID: 33643034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a Physiologically-Based Pharmacokinetic (PBPK) Model of Nebulized Hydroxychloroquine for Pulmonary Delivery to COVID-19 Patients.
    Idkaidek N; Hawari F; Dodin Y; Obeidat N
    Drug Res (Stuttg); 2021 May; 71(5):250-256. PubMed ID: 33378773
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A linked physiologically based pharmacokinetic model for hydroxychloroquine and metabolite desethylhydroxychloroquine in SARS-CoV-2(-)/(+) populations.
    Steinbronn C; Chhonker YS; Stewart J; Leingang H; Heller KB; Krows ML; Paasche-Orlow M; Bershteyn A; Stankiewicz Karita HC; Agrawal V; Laufer M; Landovitz R; Wener M; Murry DJ; Johnston C; Barnabas RV; Arnold SLM
    Clin Transl Sci; 2023 Jul; 16(7):1243-1257. PubMed ID: 37118968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Physiologically-Based Pharmacokinetics Modeling for Hydroxychloroquine as a Treatment for Malaria and Optimized Dosing Regimens for Different Populations.
    Zhai J; Ji B; Cai L; Liu S; Sun Y; Wang J
    J Pers Med; 2022 May; 12(5):. PubMed ID: 35629219
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hydroxychloroquine is Metabolized by Cytochrome P450 2D6, 3A4, and 2C8, and Inhibits Cytochrome P450 2D6, while its Metabolites also Inhibit Cytochrome P450 3A
    Paludetto MN; Kurkela M; Kahma H; Backman JT; Niemi M; Filppula AM
    Drug Metab Dispos; 2023 Mar; 51(3):293-305. PubMed ID: 36446607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Model informed dosing of hydroxycholoroquine in COVID-19 patients: Learnings from the recent experience, remaining uncertainties and gaps.
    Thémans P; Dauby N; Schrooyen L; Lebout F; Delforge M; Nasreddine R; Libois A; Payen MC; Konopnicki D; Wuillaume F; Lescrainier C; Verlinden V; Dogné JM; Hamdani J; Musuamba FT
    Br J Clin Pharmacol; 2021 Feb; 87(2):674-682. PubMed ID: 32559820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The In Vitro, In Vivo, and PBPK Evaluation of a Novel Lung-Targeted Cardiac-Safe Hydroxychloroquine Inhalation Aerogel.
    Alsmadi MM; Jaradat MM; Obaidat RM; Alnaief M; Tayyem R; Idkaidek N
    AAPS PharmSciTech; 2023 Aug; 24(6):172. PubMed ID: 37566183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hydroxychloroquine plus personal protective equipment versus standard personal protective equipment alone for the prevention of COVID-19 infections among frontline healthcare workers: the HydrOxychloroquine Prophylaxis Evaluation(HOPE) trial: A structured summary of a study protocol for a randomized controlled trial.
    Tirupakuzhi Vijayaraghavan BK; Jha V; Rajbhandari D; Myatra SN; John O; Ghosh A; Bassi A; Arfin S; Kunigari M; Joshi R; Donaldson L; Hammond N; Venkatesh B;
    Trials; 2020 Aug; 21(1):754. PubMed ID: 32867852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimizing Hydroxychloroquine Dosing for Patients With COVID-19: An Integrative Modeling Approach for Effective Drug Repurposing.
    Garcia-Cremades M; Solans BP; Hughes E; Ernest JP; Wallender E; Aweeka F; Luetkemeyer AF; Savic RM
    Clin Pharmacol Ther; 2020 Aug; 108(2):253-263. PubMed ID: 32285930
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of pantoprazole on absorption and disposition of hydroxychloroquine, a drug used in Corona Virus Disease-19 (Covid-19): A structured summary of a study protocol for a randomised controlled trial.
    Stoll F; Blank A; Mikus G; Czock D; Foerster KI; Hermann S; Häußler K; Muhareb A; Hummler S; Weiss J; Burhenne J; Haefeli WE
    Trials; 2020 Jun; 21(1):584. PubMed ID: 32600363
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hydroxychloroquine efficacy and safety in preventing SARS-CoV-2 infection and COVID-19 disease severity during pregnancy (COVID-Preg): a structured summary of a study protocol for a randomised placebo controlled trial.
    González R; García-Otero L; Pons-Duran C; Marbán-Castro E; Goncé A; Llurba E; Gil MDM; Rodríguez-Zambrano MÁ; Chen H; Ramírez M; Bardají A; Menendez C
    Trials; 2020 Jul; 21(1):607. PubMed ID: 32616063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. COVID-19 Pandemic - A Narrative Review of the Potential Roles of Chloroquine and Hydroxychloroquine.
    de Barros CM; Almeida CAF; Pereira B; Costa KCM; Pinheiro FA; Maia LDB; Trindade CM; Garcia RCT; Torres LH; Diwan S; Boralli VB
    Pain Physician; 2020 Aug; 23(4S):S351-S366. PubMed ID: 32942793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Disease on Plasma and Lung Exposure of Chloroquine, Hydroxychloroquine and Azithromycin: Application of PBPK Modeling.
    Rowland Yeo K; Zhang M; Pan X; Ban Ke A; Jones HM; Wesche D; Almond LM
    Clin Pharmacol Ther; 2020 Nov; 108(5):976-984. PubMed ID: 32531808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19.
    Singh B; Ryan H; Kredo T; Chaplin M; Fletcher T
    Cochrane Database Syst Rev; 2021 Feb; 2(2):CD013587. PubMed ID: 33624299
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of hydroxychloroquine for post-exposure prophylaxis to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among adults exposed to coronavirus disease (COVID-19): a structured summary of a study protocol for a randomised controlled trial.
    Barnabas RV; Brown E; Bershteyn A; Miller RS; Wener M; Celum C; Wald A; Chu H; Wesche D; Baeten JM;
    Trials; 2020 Jun; 21(1):475. PubMed ID: 32493478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Review on the Clinical Pharmacology of Hydroxychloroquine Sulfate for the Treatment of COVID-19.
    Cui C; Tu S; En VSJ; Li X; Yao X; Li H; Liu D
    Curr Drug Metab; 2020; 21(6):427-435. PubMed ID: 32520683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hydroxychloroquine in the treatment of adult patients with Covid-19 infection in a primary care setting (LIBERTY): A structured summary of a study protocol for a randomised controlled trial.
    Vainio PJ; Hietasalo P; Koivisto AL; Kääriäinen S; Turunen J; Virtala M; Vuorinen J; Scheinin M
    Trials; 2021 Jan; 22(1):44. PubMed ID: 33430933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hydroxychloroquine: A Physiologically-Based Pharmacokinetic Model in the Context of Cancer-Related Autophagy Modulation.
    Collins KP; Jackson KM; Gustafson DL
    J Pharmacol Exp Ther; 2018 Jun; 365(3):447-459. PubMed ID: 29438998
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ChemoPROphyLaxIs with hydroxychloroquine For covId-19 infeCtious disease (PROLIFIC) to prevent covid-19 infection in frontline healthcare workers: A structured summary of a study protocol for a randomised controlled trial.
    McEniery CM; Fisk M; Miles K; Kaloyirou F; Hubsch A; Smith J; Wilkinson IB; Cheriyan J
    Trials; 2020 Jul; 21(1):604. PubMed ID: 32616067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.